This initiative was made possible thanks to the participation of Ministère de l'Économie, de l'Innovation et des Exportations.
Managing Partner

Caprion Proteome is the leading provider of proteomics biomarker and immune monitoring services to the pharmaceutical and biotechnology industry in all phases of preclinical and clinical studies.  Its proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry (MS) platform that enables a comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Its proprietary immune monitoring platform, ImmuneCarta®, offers multiplex cell flow cytometry analysis for functional analyses of innate and adaptive immune responses. Caprion also leverages CellCarta® to develop its own internal pipeline of in-vitro diagnostic products targeting cancer, metabolic and infectious diseases.  These programs have been advanced in collaboration with world leading academic and industrial partners providing disease area expertise and access to well-qualified clinical specimens. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has over a decade of experience providing large-scale proteomics and immune monitoring services for over 50 major clients in the pharmaceutical, biotech and public sectors. Caprion acquired PPD Biomarker Discovery Sciences, LLC from PPD Inc. in 2010.  Caprion also serves as a biomarker center of excellence for the U.S. Government/NIH-NIAID for Biodefense research.

Hospital and university network supporting the initiative

The Québec - Clinical Research Organization in Cancer (Q-CROC) is a provincial interface for clinical research, bridging the gap between industry, government, healthcare establishments and the research community. To address the increasingly competitive landscape for clinical research, the Q-CROC facilitates an environment for sharing knowledge, needs and strengths, thereby enticing the conduct of studies in the province and providing patients with access to new innovative treatments. Complementary to this activity, the Q-CROC provides a niche of expertise in the discovery and validation of biomarkers to predict the response or resistance to treatment. By these engagements, the Q-CROC aims to position the province of Québec at the national and international forefront of personalized medicine in cancer, so that patients can access the most cutting-edge treatments.

Oncozyme Pharma Inc. is a Montreal-based, privately-held biopharmaceutical company, which is developing a new approach in cancer therapy, based on the inhibition of endo-exonuclease, a critical enzyme regulating cancer cell proliferation.  Oncozyme Pharma is committed to bringing new anticancer drugs to market, providing patients with true clinical benefits at a better cost/efficacy ratio.  The company is focused on the clinical development of its lead compound OCZ103 with two ongoing phase II clinical trials in colorectal cancer and lung cancer.  Oncozyme Pharma is also developing a second generation product of OCZ103, along with a discovery program on inhibitors of endo-exonuclease.

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading biopharmaceutical company.  The company is one of the largest contributors to health research in Canada. Our diversified health care portfolio includes biologic and small molecule medicines and vaccines for humans, and many of the world’s best-known consumer products.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi companies in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health). Together they employ more than 1,700 people across the country. In 2011 Sanofi companies invested $151.7 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Copyright © 2013 PMPC - All rights reserved - Website conception Könige communications